These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 18998444)

  • 1. Former pharma pitchman: beware of new drugs. An industry insider advises considering the older options if you need a prescription. Interview by Sarah Baldauf.
    Nesi T
    US News World Rep; 2008 Nov 3-10; 145(10):64. PubMed ID: 18998444
    [No Abstract]   [Full Text] [Related]  

  • 2. Don't blame it all on the bogey.
    Day M
    BMJ; 2007 Jun; 334(7606):1250-1. PubMed ID: 17569929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What ails the FDA?
    Gorelick KJ
    N Engl J Med; 2005 Jun; 352(24):2553-4. PubMed ID: 15958814
    [No Abstract]   [Full Text] [Related]  

  • 4. Why is this woman smiling? The hard sell of bad medicine.
    Bloice C
    Revolution (Oakl); 2005; 6(1):22-9. PubMed ID: 15822700
    [No Abstract]   [Full Text] [Related]  

  • 5. Withdrawal of rofecoxib - a wake up call for drug safety.
    Mishra P; Palaian S
    Kathmandu Univ Med J (KUMJ); 2004; 2(4):360. PubMed ID: 16388250
    [No Abstract]   [Full Text] [Related]  

  • 6. Evaluating drug effects in the post-Vioxx world: there must be a better way.
    Avorn J
    Circulation; 2006 May; 113(18):2173-6. PubMed ID: 16684873
    [No Abstract]   [Full Text] [Related]  

  • 7. Withdrawal syndrome.
    Nat Med; 2004 Nov; 10(11):1143. PubMed ID: 15516887
    [No Abstract]   [Full Text] [Related]  

  • 8. The story of Vioxx--no pain and a lot of gain: ethical concerns regarding conduct of the pharmaceutical industry.
    Cahana A; Mauron A
    J Anesth; 2006; 20(4):348-51. PubMed ID: 17072707
    [No Abstract]   [Full Text] [Related]  

  • 9. Drug safety special: the safety catch.
    Wadman M
    Nature; 2005 Mar; 434(7033):554-6. PubMed ID: 15800591
    [No Abstract]   [Full Text] [Related]  

  • 10. Vioxx's history and the need for better procedures and better testing.
    Gilhooley M
    Seton Hall Law Rev; 2007; 37(4):941-68. PubMed ID: 18363218
    [No Abstract]   [Full Text] [Related]  

  • 11. Drug safety special: chasing shadows.
    Frantz S
    Nature; 2005 Mar; 434(7033):557-8. PubMed ID: 15800592
    [No Abstract]   [Full Text] [Related]  

  • 12. Vioxx should be allowed back on the market advises expert panel.
    Sibbald B
    CMAJ; 2006 Aug; 175(3):234. PubMed ID: 16880435
    [No Abstract]   [Full Text] [Related]  

  • 13. What is a 'safe' drug?
    Healy B
    US News World Rep; 2004 Dec; 137(21):37. PubMed ID: 15636504
    [No Abstract]   [Full Text] [Related]  

  • 14. Sending pharma better signals.
    Avorn J
    Science; 2005 Jul; 309(5735):669. PubMed ID: 16051753
    [No Abstract]   [Full Text] [Related]  

  • 15. Drug safety on trial.
    Nature; 2005 Mar; 434(7033):545. PubMed ID: 15800579
    [No Abstract]   [Full Text] [Related]  

  • 16. Quebec allows Vioxx class-action suit.
    Sibbald B
    CMAJ; 2007 Jan; 176(1):20. PubMed ID: 17200378
    [No Abstract]   [Full Text] [Related]  

  • 17. Merck's actions surrounding Vioxx.
    Heinley M
    PLoS Med; 2006 Jun; 3(6):e286; author reply e285. PubMed ID: 16789808
    [No Abstract]   [Full Text] [Related]  

  • 18. [Cyclooxygenase inhibitors: a never ending story?].
    Macrì R; Manfredi C
    G Ital Cardiol (Rome); 2006 Jul; 7(7):505-7. PubMed ID: 16977790
    [No Abstract]   [Full Text] [Related]  

  • 19. Drug safety and regulation.
    Waller PC; Evans SJ; Beard K
    BMJ; 2005 Jul; 331(7507):4-5. PubMed ID: 15994664
    [No Abstract]   [Full Text] [Related]  

  • 20. How the New England Journal missed warning signs on Vioxx: medical weekly waited years to report flaws in article that praised pain drug; Merck seen as "punching bag".
    Armstrong D
    Wall St J (East Ed); 2006 May; ():A1, A10. PubMed ID: 16848016
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.